Intersect ENT Inc (NASDAQ:XENT) General Counsel David Aaron Lehman sold 36,000 shares of Intersect ENT stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $32.75, for a total transaction of $1,179,000.00. Following the completion of the sale, the general counsel now owns 45,000 shares of the company’s stock, valued at $1,473,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Intersect ENT Inc (NASDAQ:XENT) opened at $31.85 on Friday. Intersect ENT Inc has a 52-week low of $11.00 and a 52-week high of $34.40.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The company had revenue of $22.31 million for the quarter, compared to analyst estimates of $21.53 million. During the same quarter last year, the firm posted ($0.22) earnings per share. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. sell-side analysts expect that Intersect ENT Inc will post -0.63 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in Intersect ENT by 247.7% during the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock worth $41,447,000 after acquiring an additional 1,056,389 shares during the period. Alliancebernstein L.P. increased its position in Intersect ENT by 2,746.9% during the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock worth $26,036,000 after acquiring an additional 898,785 shares during the period. Lord Abbett & CO. LLC bought a new position in Intersect ENT during the second quarter worth $9,384,000. EAM Investors LLC bought a new position in Intersect ENT during the second quarter worth $4,542,000. Finally, State Street Corp increased its position in Intersect ENT by 33.6% during the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock worth $15,437,000 after acquiring an additional 138,968 shares during the period. 86.31% of the stock is currently owned by institutional investors.
A number of analysts have issued reports on XENT shares. Bank of America lifted their target price on shares of Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Zacks Investment Research lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Canaccord Genuity lifted their price target on shares of Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Northland Securities reissued a “hold” rating and issued a $25.00 price target on shares of Intersect ENT in a research report on Friday, November 3rd. Finally, BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research report on Tuesday, November 7th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $32.29.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.